
Opinion|Videos|March 24, 2025
Establishing Atopic Dermatitis Treatment Goals and Expectations With Patients
Panelists discuss how establishing realistic treatment goals for patients with moderate to severe atopic dermatitis requires collaborative conversations addressing itch reduction, sleep improvement, and quality-of-life enhancement, whereas decisions to initiate systemic therapy are driven by inadequate response to optimized topical regimens, disease impact on daily functioning, recurrent flares, significant psychological burden, treatment adherence challenges, and the recognition that early intervention may prevent disease progression and comorbidities.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you discuss treatment goals for moderate to severe atopic dermatitis with your patients and their families?
- How do you decide when it is time to initiate systemic therapy for patients with atopic dermatitis?
Advertisement
Related to this article

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
Conservative Therapy in Fibrillary GN: A Four-Drug Kidney-Protective Approach
3
3 Hematology Headlines You Missed in September 2026
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5

